BioLineRX Ltd. : BioLineRx Highlights Initial Phase 2 Results of Acute Myeloid …4-traders (press release)Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow m…
Using the Immune System to Fight LupusdailyRxRituximab (brand name Rituxan) targets B cells to decrease their number. It has been approved for use in leukemias, lymphomas and autoimmune diseases involving B cells. However, a clinical trial using rituxi…
ProHealth |
The 2nd International Symposium For CFS/ME Overview By Rosamund Vallings …
ProHealth Other interventions include rituximab, cytokine blockers and GcMAF. [Dr. Peterson’s assertion that a drug can be a ‘biomarker’ refers to the idea of segregating patients according to their response to treatment, and then digging into their physiology … |
MedPage Today10 Questions: Robert Spiera, MDMedPage TodayIn the ensuing nearly 2 decades, many other such biologics have been developed for the treatment of rheumatoid arthritis, lupus, and with the demonstration of the efficacy of rituximab in ANCA-as…
MedscapeTop 10 Highlights From The Liver MeetingMedscapeInterim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study. Program and abstracts of the 64th Annual Meeting…
|
Biologic Makers Thwart Generics: Winning Stocks
YCharts Hospira (HSP) and Teva halted late-stage development of follow-on versions of Roche AG’s monoclonal antibody Rituxan (rituximab) — $3.1 billion in domestic sales, trailing 12-months – due to rising R&D costs. Similar to strategies used to delay entry … |
Monoclonal Antibody Industry for Global & China Markets Forecasts to 2017 in …DigitalJournal.comIn 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) a…
Teva Announces Additional Regulatory Exclusivity for TREANDA …Lifescience-onlineTREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with ritux…
Global and China Monoclonal Antibody Industry Report, 2013 – 2017SBWire (press release)In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab …
Global and China Monoclonal Antibody Industry with 2017 ForecastsThe International News MagazineIn 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Tra…